BR112023021918A2 - Composto como antagonista do receptor de adenosina a2a e composição farmacêutica compreendendo o mesmo - Google Patents
Composto como antagonista do receptor de adenosina a2a e composição farmacêutica compreendendo o mesmoInfo
- Publication number
- BR112023021918A2 BR112023021918A2 BR112023021918A BR112023021918A BR112023021918A2 BR 112023021918 A2 BR112023021918 A2 BR 112023021918A2 BR 112023021918 A BR112023021918 A BR 112023021918A BR 112023021918 A BR112023021918 A BR 112023021918A BR 112023021918 A2 BR112023021918 A2 BR 112023021918A2
- Authority
- BR
- Brazil
- Prior art keywords
- same
- adenosine
- pharmaceutical composition
- receptor antagonist
- compound
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title abstract 3
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210053352 | 2021-04-23 | ||
| PCT/IB2022/053721 WO2022224180A1 (en) | 2021-04-23 | 2022-04-21 | Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021918A2 true BR112023021918A2 (pt) | 2023-12-19 |
Family
ID=83722733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021918A BR112023021918A2 (pt) | 2021-04-23 | 2022-04-21 | Composto como antagonista do receptor de adenosina a2a e composição farmacêutica compreendendo o mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240217978A1 (https=) |
| EP (1) | EP4326724A4 (https=) |
| JP (1) | JP7646873B2 (https=) |
| KR (1) | KR102863028B1 (https=) |
| CN (1) | CN117120443A (https=) |
| AU (1) | AU2022262777C1 (https=) |
| BR (1) | BR112023021918A2 (https=) |
| CA (1) | CA3207935A1 (https=) |
| MX (1) | MX2023012338A (https=) |
| TW (1) | TWI838736B (https=) |
| WO (1) | WO2022224180A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023296161A1 (en) * | 2022-06-13 | 2025-01-02 | Alivexis, Inc. | Azacycloalkyl carbonyl cyclic amine compound |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0459702A1 (en) * | 1990-05-29 | 1991-12-04 | Zeneca Limited | Azole Derivatives |
| US5356894A (en) | 1990-05-29 | 1994-10-18 | Rodney Peter W | Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist |
| CA2148502A1 (en) * | 1993-09-06 | 1995-03-16 | Fumio Suzuki | Antidepressants |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6664252B2 (en) * | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| CA2459304A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| IL161573A0 (en) * | 2001-11-30 | 2004-09-27 | Schering Corp | [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS |
| JPWO2003068776A1 (ja) * | 2002-02-15 | 2005-06-02 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| WO2004092173A2 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
| EP3810610A1 (en) * | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| JP7197206B2 (ja) * | 2018-06-26 | 2022-12-27 | チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド | Ａ２ａ受容体拮抗薬として用いられるトリアゾロトリアジン誘導体 |
| AU2019383948A1 (en) * | 2018-11-20 | 2021-05-20 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| CN112028891B (zh) * | 2019-07-30 | 2022-07-05 | 厦门宝太生物科技股份有限公司 | 腺苷受体拮抗剂 |
-
2022
- 2022-04-21 MX MX2023012338A patent/MX2023012338A/es unknown
- 2022-04-21 AU AU2022262777A patent/AU2022262777C1/en active Active
- 2022-04-21 TW TW111115277A patent/TWI838736B/zh active
- 2022-04-21 EP EP22791230.0A patent/EP4326724A4/en active Pending
- 2022-04-21 KR KR1020220049770A patent/KR102863028B1/ko active Active
- 2022-04-21 BR BR112023021918A patent/BR112023021918A2/pt unknown
- 2022-04-21 CA CA3207935A patent/CA3207935A1/en active Pending
- 2022-04-21 US US18/287,743 patent/US20240217978A1/en active Pending
- 2022-04-21 WO PCT/IB2022/053721 patent/WO2022224180A1/en not_active Ceased
- 2022-04-21 CN CN202280022844.9A patent/CN117120443A/zh active Pending
- 2022-04-21 JP JP2023565293A patent/JP7646873B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024515739A (ja) | 2024-04-10 |
| JP7646873B2 (ja) | 2025-03-17 |
| KR102863028B1 (ko) | 2025-09-22 |
| AU2022262777C1 (en) | 2025-02-13 |
| WO2022224180A1 (en) | 2022-10-27 |
| TW202302593A (zh) | 2023-01-16 |
| AU2022262777A1 (en) | 2023-09-21 |
| MX2023012338A (es) | 2023-10-30 |
| US20240217978A1 (en) | 2024-07-04 |
| CN117120443A (zh) | 2023-11-24 |
| TWI838736B (zh) | 2024-04-11 |
| AU2022262777B2 (en) | 2024-11-07 |
| EP4326724A4 (en) | 2025-03-26 |
| CA3207935A1 (en) | 2022-10-27 |
| EP4326724A1 (en) | 2024-02-28 |
| KR20220146348A (ko) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001625A1 (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| BR112022008375A2 (pt) | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| BR112022009209A2 (pt) | Derivado de amida e método de preparação e uso do mesmo na medicina | |
| BRPI0819319B8 (pt) | análogos de aminoglicosídeo antibacteriano | |
| BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
| BR112023022735A2 (pt) | Derivado de fosfonila e composição e aplicação farmacêutica do mesmo | |
| CY1116328T1 (el) | Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης | |
| BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
| UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| UY29384A1 (es) | Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes. | |
| CR20140515A (es) | Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| MA32812B1 (fr) | Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale | |
| MX393820B (es) | Derivado de ?-aminoácido tricíclico fusionado, método de preparación, y uso médico del mismo. | |
| CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
| UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
| CR11825A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
| EA202192845A1 (ru) | Новые композиции, содержащие мелфлуфен | |
| MX2021014287A (es) | Nuevos antagonistas ciclicos del receptor b2 de bradiquinina. | |
| CO2023000854A2 (es) | Nuevo derivado de pirazol | |
| CL2022001317A1 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma. | |
| MX2021000403A (es) | Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma. | |
| BR112023021918A2 (pt) | Composto como antagonista do receptor de adenosina a2a e composição farmacêutica compreendendo o mesmo |